Sökning: "phosphorylations"

Visar resultat 1 - 5 av 31 avhandlingar innehållade ordet phosphorylations.

  1. 1. Mdm2 phosphorylations : characterization and applications

    Författare :Maria Malmlöf; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Cancer is a widespread disease. In spite of all research resulting in new improved therapies, there are still many tumors that cannot be cured. To oppose that, also a preventive research approach is important with goals such as decreasing the human exposure to carcinogens. LÄS MER

  3. 2. Signaling for color change in melanophores : and a biosensor application

    Författare :Annika M. Karlsson; Samuel Svensson; Margareta Wallin; Linköpings universitet; []
    Nyckelord :color change; melanophores; tyrosine; phosphorylations; melatonin; nitric oxide; MEDICINE; MEDICIN;

    Sammanfattning : Melanophores are dark brown pigment cells located in the skin of fish, amphibia, reptiles, and many invertebrates. The color of the animal can change via rearrangement of pigment granules, melanosomes, in the cells. The dark melanophores can either hide colorful cells so that the animal appears dark, or let through colors from underneath. LÄS MER

  4. 3. Xenobiotics-induced phosphorylations of MDM2

    Författare :Gerd Pääjärvi; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The aim of the present study was to characterize the Mdm2 and p53 responses induced by DNA damaging xenobiotics and how these responses can be modified by non-genotoxic xenobiotics. During control conditions cellular levels of p53 are low. The level is regulated by Mdm2 and Mdm2 and p53 forms an autoregulatory loop. LÄS MER

  5. 4. The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations : a crosstalk with potential to predict tamoxifen resistance in breast cancer

    Författare :Josefine Bostner; Olle Stål; Cecilia Bivik; Malin Sund; Linköpings universitet; []
    Nyckelord :;

    Sammanfattning : Estrogen receptor α content is the primary breast cancer biomarker distinguishing the patients responsive from the non-responsive to endocrine treatments. Tamoxifen is an estrogen competitor with large potential to treat breast cancer patients and prolongs time to recurrence. LÄS MER

  7. 5. Phosphorylation of ERα and HIF-1α in breast cancer with focus on tamoxifen response and links to kinase activation

    Författare :Caroline Wigerup; Malmö Patologi; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Sammanfattning : Anti-oestrogens are commonly used in adjuvant breast cancer treatment and for a long time tamoxifen has been the main endocrine treatment. Patients who are eligibly for endocrine treatment are selected by the tumour-specific expression of oestrogen receptor (ER) and approximately 70 % of all breast cancer patients are classified as ER positive. LÄS MER